| 27 May, 05:36 pm | — | … | Marksans Pharma Ltd - 524404 - Compliances-Reg.24(A)-Annual Secretarial Compliance | bse |
| 26 May, 01:34 pm | — | … | Marksans Pharma Ltd - 524404 - Corporate Action-Board approves Dividend | bse |
| 26 May, 01:32 pm | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "Marksans Pharma Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT ₹3,000 Cr Net Income Guidance Delivered". | nse |
| 26 May, 01:30 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 26 May, 01:28 pm | — | … | Marksans Pharma Limited has informed the Exchange about Investor Presentation | nse |
| 26 May, 01:26 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 26 May, 01:15 pm | — | … | Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 0.90 per equity share. | nse |
| 26 May, 01:13 pm | — | … | Marksans Pharma Ltd - 524404 - Audited Financial Results For The Quarter And Year Ended 31 March, 2026 | bse |
| 26 May, 01:10 pm | — | … | Marksans Pharma Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2026. | nse |
| 26 May, 12:54 pm | — | … | Marksans Pharma Ltd - 524404 - Board Meeting Outcome for Outcome Of Board Meeting Held On 26 May, 2026 | bse |
| 19 May, 12:48 pm | — | … | Marksans Pharma Limited has informed the Exchange about Schedule of conference call for analysts and investors on Wednesday, May 27, 2026 at 04:30 PM (IST) to discuss the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026 | nse |
| 19 May, 11:02 am | — | … | Marksans Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | nse |
| 12 May, 03:05 pm | — | … | Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results And To Consider Recommendation Of Dividend If Any, For The Financial Year Ended March 31, 2026 | bse |
| 01 Apr, 12:17 pm | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)". | nse |
| 01 Apr, 12:11 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 11 Mar, 04:34 pm | — | … | Marksans Pharma Limited has informed the Exchange about opening of Special Window for Re-lodgment of Transfer Requests of Physical Shares | nse |
| 10 Mar, 04:54 pm | — | … | Marksans Pharma Limited has informed the Exchange about its Official's participation in Investec India Promoter & Founder conference 2026 | nse |
| 12 Feb, 04:07 pm | — | … | Marksans Pharma Limited transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026 | nse |
| 12 Feb, 04:03 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | bse |
| 06 Feb, 06:35 pm | — | … | Marksans Pharma Limited has informed the Exchange about Link of Recording | nse |
| 06 Feb, 06:29 pm | — | … | Marksans Pharma Limited has informed the Exchange about Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results | nse |
| 06 Feb, 06:25 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 06 Feb, 04:35 pm | — | … | Marksans Pharma Limited has informed the Exchange about Newspaper Publication of Un-Audited financial results for the quarter and nine months ended December 31, 2025 | nse |
| 05 Feb, 02:05 pm | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "unaudited financial results for Q3 FY26". | nse |
| 05 Feb, 02:02 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 05 Feb, 01:57 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 05 Feb, 01:54 pm | — | … | Marksans Pharma Limited has informed the Exchange about Investor Presentation | nse |
| 05 Feb, 01:44 pm | — | … | Marksans Pharma Ltd - 524404 - Unaudited Financial Results For The Quarter And Nine Months Ended 31 December, 2025 | bse |
| 05 Feb, 01:36 pm | — | … | Marksans Pharma Limited has informed the Exchange regarding approval of Unaudited financial results for the quarter and nine months ended 31 December, 2025 | nse |
| 27 Jan, 02:16 pm | — | … | Marksans Pharma Limited has informed the Exchange about incorporation of two new wholly owned subsidiary companies | nse |
| 27 Jan, 02:16 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Acquisition | bse |
| 22 Jan, 04:43 pm | — | … | Marksans Pharma Limited has informed the Exchange about schedule of a conference call for analysts and investors on Friday, February 06, 2026 at 04:00 PM (IST) to discuss the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended December 31, 2025 | nse |
| 09 Jan, 03:32 pm | — | … | Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Declaration Of Quarterly Results For The Quarter Ended December 31, 2025 | bse |
| 21 Nov, 12:13 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 21 Nov, 11:58 am | — | … | Marksans Pharma Limited has informed the Exchange about Transcript | nse |
| 20 Nov, 01:12 pm | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated November 20, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution". | nse |
| 20 Nov, 01:06 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 19 Nov, 11:23 am | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated November 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC)". | nse |
| 19 Nov, 11:15 am | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 17 Nov, 11:27 am | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its Products from UK MHRA.". | nse |
| 17 Nov, 11:18 am | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 17 Nov, 09:51 am | — | … | Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding unaudited financial results for the quarter and half year ended September 30, 2025. | nse |
| 14 Nov, 08:01 pm | — | … | Marksans Pharma Limited has informed the Exchange about Link of Recording | nse |
| 14 Nov, 07:56 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | bse |
| 13 Nov, 08:08 pm | — | … | Marksans Pharma Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Marksans Pharma Limited Press Release regarding unaudited financial results for the quarter and half year ended September 30, 2025". | nse |
| 13 Nov, 08:05 pm | — | … | Marksans Pharma Limited has informed the Exchange about Investor Presentation | nse |
| 13 Nov, 07:57 pm | — | … | Marksans Pharma Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2025. | nse |
| 13 Nov, 07:47 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | bse |
| 13 Nov, 07:42 pm | — | … | Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation | bse |
| 13 Nov, 07:38 pm | — | … | Marksans Pharma Ltd - 524404 - Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025 | bse |